Treatment of Invasive Candida Infections in the Neonatal Intensive Care Unit
- First Online:
- Cite this article as:
- Andrews, M.G., Patel, R. & Miller, J. Curr Fungal Infect Rep (2013) 7: 96. doi:10.1007/s12281-013-0134-1
- 154 Downloads
Invasive Candida infections are a leading cause of morbidity and mortality in the neonatal intensive care unit (NICU). Extremely preterm and very low birth weight infants are at the highest risk of infection. There are currently no antifungal agents that have FDA-labeling for the treatment of invasive candidiasis in the neonatal population. Based on the current IDSA guidelines, amphotericin and fluconazole are considered first-line options for neonatal candidiasis. The newer antifungal agents (i.e., echinocandins and voriconazole) are currently considered second-line or salvage therapy; however, evidence supporting their use is emerging. This review focuses on the supporting evidence for the selection of antifungal agents for treatment of invasive Candida infections in the NICU.